Biological significance of interleukin-6 secretion on cancer immunotherapy with interleukin-2

International Journal of Immunotherapy

Volumn 12, Issue 3-4, 1996, Pages 49-52

  Lissoni, P ^a   Fumagalli, L ^b   Barni, S ^a   Di Felice, G ^b   Ardizzoia, A ^a   Maiorca, F ^b   Tancini, G ^a  

^a SAN GERARDO HOSPITAL   (Italy)

^b Ospedale San Gerardo ^*

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 6;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; KIDNEY METASTASIS; PHASE 2 CLINICAL TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030390521     PISSN: 02559625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Kishimoto T. The biology of interleukin-6. Blood, 74, 1989, 1
2. Chen L , Zilberstein A , Ravel M Growth inhibition of breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon-β2 Proc Natl Acad Sci. USA, 85, 1980, 8037.
3. Tartour E et al Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients Br. J. Cancer, 69, 1994, 911.
4. Lissoni P et al Relation between macrophage and T helper-2 lymphocyte functions in human neoplasms. Neopterin. interleukin-10 and interleukin-6 blood levels in early or advanced solid tumors J Biol Reg Homeost Agents, 9, 1995, 146
5. Broder S , Muul L., Waidmann T A Suppressor cells in neoplastic disease J Natl. Cancer Inst. 1978, 5.
6. Meffert M. et al. In vivo time and dose dependency of interlukin-6 secretion in response to low-dose subcutaneous recombinant interleukin-2 Cancer Biother., 9, 1994, 307
7. Rosenberg S A The immunotherapy and gene therapy of cancer J Clin Oncol, 10, 1992, 180